ContextVision AB (publ)

Oslo Stock Exchange CONTX.OL

ContextVision AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: 55.76%

ContextVision AB (publ) Return on Capital Employed (ROCE) is 55.76% for the year ending December 31, 2023, a -7.32% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

ContextVision AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 60.16%, a -33.99% change year over year.
ContextVision AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 91.14%, a 60.77% change year over year.
ContextVision AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 56.69%, a 306.69% change year over year.
ContextVision AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 13.94%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Oslo Stock Exchange: CONTX.OL

ContextVision AB (publ)

CEO	Dr. Gerald Potzsch
IPO Date	Jan. 3, 2000
Location	Sweden
Headquarters	HollAendargatan 13, 2 tr
Employees	41
Sector	Technology
Industries Augmented Reality (AR) Gaming Software Medical Instruments

Description

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; and GOPiCE, a technology for volumetric image enhancement in real-time. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; and INIFY Prostate Screening for digital analysis of prostate biopsies. The company was founded in 1983 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years